- Home
- GLPG vs FOLD Comparison
GLPG vs FOLD Comparison
Compare GLPG & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- FOLD
- Stock Information
- Founded
- GLPG 1999
- FOLD 2002
- Country
- GLPG Belgium
- FOLD United States
- Employees
- GLPG N/A
- FOLD N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- FOLD Biotechnology: Pharmaceutical Preparations
- Sector
- GLPG Health Care
- FOLD Health Care
- Exchange
- GLPG Nasdaq
- FOLD Nasdaq
- Market Cap
- GLPG 2.1B
- FOLD 2.5B
- IPO Year
- GLPG 2005
- FOLD 2007
- Fundamental
- Price
- GLPG $34.45
- FOLD $8.35
- Analyst Decision
- GLPG Sell
- FOLD Strong Buy
- Analyst Count
- GLPG 3
- FOLD 9
- Target Price
- GLPG $26.00
- FOLD $26.44
- AVG Volume (30 Days)
- GLPG 203.5K
- FOLD 5.8M
- Earning Date
- GLPG 10-29-2025
- FOLD 11-05-2025
- Dividend Yield
- GLPG N/A
- FOLD N/A
- EPS Growth
- GLPG N/A
- FOLD N/A
- EPS
- GLPG N/A
- FOLD N/A
- Revenue
- GLPG $323,674,692.00
- FOLD $571,160,000.00
- Revenue This Year
- GLPG $1.77
- FOLD $21.04
- Revenue Next Year
- GLPG $0.44
- FOLD $21.34
- P/E Ratio
- GLPG N/A
- FOLD N/A
- Revenue Growth
- GLPG 5.43
- FOLD 25.35
- 52 Week Low
- GLPG $22.36
- FOLD $5.51
- 52 Week High
- GLPG $37.78
- FOLD $12.65
- Technical
- Relative Strength Index (RSI)
- GLPG 53.87
- FOLD 59.80
- Support Level
- GLPG $32.37
- FOLD $8.01
- Resistance Level
- GLPG $37.78
- FOLD $8.59
- Average True Range (ATR)
- GLPG 0.77
- FOLD 0.37
- MACD
- GLPG 0.00
- FOLD -0.03
- Stochastic Oscillator
- GLPG 39.37
- FOLD 75.00
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.